Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
ECHELON-2 Study Group
Lymphoma-Myeloma
Research output
:
Contribution to journal
›
Article
›
peer-review
509
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Brentuximab Vedotin
100%
Peripheral T-Cell Lymphoma
85%
Drug Therapy
36%
Vincristine
33%
Prednisone
32%
Cyclophosphamide
29%
Doxorubicin
28%
Progression-Free Survival
28%
Placebos
21%
Safety
18%
Anaplastic Large-Cell Lymphoma
14%
Febrile Neutropenia
13%
National Cancer Institute (U.S.)
12%
Peripheral Nervous System Diseases
10%
National Institutes of Health (U.S.)
10%
Random Allocation
10%
Pathology
6%
Survival
5%
Incidence
5%
Pharmaceutical Preparations
4%
Therapeutics
3%
Neoplasms
3%